In the Boardroom
Refine Search
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Pharmaceutical
GlaxoSmithKline’s Christine Roth is to leave the company to become the new head of the Oncology Strategic Business Unit at Bayer’s (BAYN: DE) Pharmaceuticals division. 4 February 2022
Pharmaceutical
Japan’s largest drugmaker Takeda Pharmaceutical today announced changes to its executive leadership team to continue driving long-term growth in a highly competitive and dynamic global marketplace. 3 February 2022
Pharmaceutical
Swiss pharma giant Roche today announced that Dr William Pao, head of Roche pharma research and early development (pRED) since 2018, has decided to leave Roche for a new opportunity and return to the USA, effective March 18, 2022. 2 February 2022
Biotechnology
Shares of Finnish clinical-stage biopharma Faron Pharmaceutical were up 4.7% at 254 pence this morning as it announced the appointment of Juho Jalkanen as chief operating officer of the company. 31 January 2022
Biotechnology
UK gene and cell therapy group Oxford Biomedica and US genetic medicines company Homology Medicines have agreed to establish a high-performing, full scope adeno-associated virus (AAV) manufacturing and innovation business in the USA. 28 January 2022
Biotechnology
Replacing its retiring co-founder and chief executive Onno van de Stolpe, Belgium-based biotech Galapagos today announced that industry veteran Paul Stoffels will join the company as CEO effective April 1. 27 January 2022
Pharmaceutical
Once touted as a potential successor to Merck & Co’s former boss Kenneth Frazier, Frank Clyburn is to leave his post as the company’s executive vice president and president, Human Health, to take up a role elsewhere. 21 January 2022
Biotechnology
Austrian drug developer Marinomed Biotech today announced the appointment of Dr Cornelia Kutzer as chief business officer (CBO) of the company. 21 January 2022
Biotechnology
New biotech company Altos Labs has launched today with the aim of unraveling the deep biology of cellular rejuvenation programming, with $3 billion fully committed from renowned company builders and investors. 19 January 2022
Biotechnology
Polish biotech Ryvu Therapeutics has announced the appointment of Dr Hendrik Nogai to the role of chief medical officer effective February 1, 2022. 17 January 2022
Pharmaceutical
German life sciences company Merck KGaA today announced new appointments in global R&D and strategy leadership for the Healthcare business sector. 13 January 2022
Biotechnology
California-based insitro, a machine learning-driven drug discovery and development company, has announced the expansion of its leadership team. 12 January 2022
Biotechnology
US clinical stage cell and gene therapy company Castle Creek Biosciences says it has acquired Novavita Thera, a pre-clinical gene therapy company focused on rare liver and metabolic diseases. 11 January 2022
Biotechnology
Aiming to expand its rare diseases gene therapy portfolio, USA-based Kriya Therapeutics revealed on Friday it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). 8 January 2022
Biotechnology
Eikon Therapeutics, a pioneer in the application of live-cell super-resolution microscopy to drug discovery, has closed a $517.8 million Series B financing. 7 January 2022
Biotechnology
US precision cancer therapy specialist Blueprint Medicines has appointed Kate Haviland to succeed Jeff Albers as chief executive (CEO), effective April 4, 2022. 6 January 2022
Biosimilars
Effective January 3, German drugmaker STADA Arzneimittel is strengthening its biosimilars capabilities with the appointment of Erin Federman as global commercial head, Biosimilars and vice president. 5 January 2022
Biotechnology
Anders Ullman, currently a member of the board of directors at Swedish Orphan Biovitrum, also known as Sobi, will become head of R&D and chief medical officer and replace Dr Ravi Rao. 13 December 2021
Biotechnology
Swiss biotech ImmunOs Therapeutics today announced that Steve Coats has been appointed as chief development officer (CDO). 6 December 2021
Pharmaceutical
Privately-held Danish medical dermatology specialist LEO Pharma today said that its president and chief executive of two years, Catherine Mazzacco, has resigned from the position and will be leaving the company as of today. 30 November 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze